ZED 3197
Alternative Names: ZED-3197Latest Information Update: 19 Dec 2023
At a glance
- Originator Zedira GmbH
- Class Anticoagulants; Antithrombotics; Peptidomimetics; Small molecules
- Mechanism of Action Factor XIIIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Blood coagulation disorders
Most Recent Events
- 19 Dec 2023 Preclinical trials in Blood coagulation disorders in Germany (IV) (Zedira pipeline, December 2023)
- 11 Dec 2023 ZED 3197 is available for licensing as of 11 Dec 2023. https://zedira.com/Business-Development